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Research
Bisphenol A (BPA) is a ubiquitous   chemical 
widely used in the manufacture of poly­
carbonate plastics found in some water bottles 
(Brede et al. 2003), the lining of food and bev­
erage cans and water pipes (Bae et al. 2002), 
and some dental sealants and composites 
(Joskow et al. 2006; Sasaki et al. 2005). BPA 
can also be used in the manufacture of ther­
mal receipt paper (Biedermann et al. 2010; 
vom Saal and Myers 2008). Widespread use 
of BPA­containing consumer products has led 
to ubiquitous exposure to BPA in the general 
population (Vandenberg et al. 2007). In the 
2003–2004 National Health and Nutrition 
Examination Survey (NHANES), BPA was 
detected in > 90% of urine samples obtained 
from a representative sample of U.S. residents 
(Calafat et al. 2008). Detectable concentrations 
of BPA have also been measured in human 
folli  cular fluid (1–2 µg/L) and amniotic fluid 
(1–9 µg/L) (Ikezuki et al. 2002), suggesting 
that exposure may occur as early as the peri­
conception period.
During the past several decades, infertil­
ity rates have increased, and approximately 
10–15% of couples in the United States and 
other developed countries are infertile (Fritz 
and Speroff 2011), in part because of delayed 
childbearing. An important determinant 
of reduced fertility is failed implantation, 
which is thought to account for 50–75% 
of preclinical pregnancy losses in humans 
(Macklon et al. 2002; Norwitz et al. 2001). 
Implantation is orchestrated and regulated 
by a very carefully synchronized interplay of 
hormonal signals and feedback loops, making 
it potentially vulnerable to chemicals such as 
BPA that may disrupt endocrine signaling 
(Berger et al. 2010; Ma et al. 2003; Varayoud 
et al. 2011).
Although BPA has been known to have 
estrogenic properties since 1936 (Dodds and 
Lawson 1936), the biological activity of BPA 
is rather complex and still not fully under­
stood. More recently in in vitro studies, BPA 
was found to have measurable activity in mul­
tiple assays involving signaling pathways for 
estrogen, androgen, and thyroid hormones 
(Food and Agriculture Organization of the 
United Nations / World Health Organization 
2010; Lee et al. 2003; Quesada et al. 2002; 
Welshons et al. 2006; Wozniak et al. 2005). 
These hormonal effects may contribute to a 
disruption of reproductive function. In addi­
tion, experimental studies in animals suggest 
that BPA exposure adversely affects female 
fertility (Berger et al. 2007, 2008, 2010; 
Takai et al. 2001; Tsutsui et al. 1998). An 
increased incidence of failed intrauterine 
implantation was observed in mice after sub­
cutaneous exposure to environmentally rele­
vant low concentrations of BPA (Takai et al. 
2001; Tsutsui et al. 1998). Litter size, num­
ber of implantation sites, and the percent­
age of females delivering pups were decreased 
after single­dose administration of BPA dur­
ing the critical time window for implantation. 
Similar effects were observed in mice after 
ingestion and subcutaneous administration 
of higher doses of BPA (Berger et al. 2007, 
2008, 2010; Xiao et al. 2011).
Few human studies have examined the 
association of BPA with female fertility and 
pregnancy outcomes, primarily because of the 
practical challenges involved in studying early 
pregnancy end points among couples conceiv­
ing naturally (Fujimoto et al. 2011; Mok­Lin 
et al. 2010; Sugiura­Ogasawara et al. 2005). 
Therefore, we investigated the relationship 
between urinary BPA concentrations and 
implantation failure among women under­
going in vitro fertilization (IVF).
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Ba c k g r o u n d: Bisphenol A (BPA) is a synthetic chemical widely used in the production of 
  polycarbonate plastic and epoxy resins found in numerous consumer products. In experimental 
animals, BPA increases embryo implantation failure and reduces litter size.
oB j e c t i v e: We evaluated the association of urinary BPA concentrations with implantation failure 
among women undergoing in vitro fertilization (IVF).
Me t h o d s : We used online solid phase extraction–high performance liquid chromatography–
isotope dilution tandem mass spectrometry to measure urinary BPA concentrations in 137 women 
in a prospective cohort study among women undergoing IVF at the Massachusetts General 
Hospital Fertility Center in Boston, Massachusetts. We used logistic regression to evaluate the 
association of cycle-specific urinary BPA concentrations with implantation failure, accounting for 
correlation among multiple IVF cycles in the same woman using generalized estimating equations. 
Implantation failure was defined as a negative serum β-human chorionic gonadotropin test (β-hCG 
< 6 IU/L) 17 days after egg retrieval.
re s u l t s: Among 137 women undergoing 180 IVF cycles, urinary BPA concentrations had a geo-
metric mean (SD) of 1.53 (2.22) µg/L. Overall, 42% (n = 75) of the IVF cycles resulted in implan-
tation failure. In adjusted models, there was an increased odds of implantation failure with higher 
quartiles of urinary BPA concentrations {odds ratio (OR) 1.02 [95% confidence interval (CI): 0.35, 
2.95}, 1.60 (95% CI: 0.70, 3.78), and 2.11 (95% CI: 0.84, 5.31) for quartiles 2, 3, and 4, respec-
tively, compared with the lowest quartile (p-trend = 0.06).
co n c l u s i o n: There was a positive linear dose–response association between BPA urinary concen-
trations and implantation failure.
key w o r d s : bisphenol A, embryo implantation, fertility, human, reproduction, women. Environ 
Health Perspect 120:978–983 (2012).  http://dx.doi.org/10.1289/ehp.1104307 [Online 6 April 
2012]Bisphenol A and implantation failure in women
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Methods
Study participants and data collection. The 
present analysis of 137 women is part of a 
larger prospective cohort study designed 
to investigate the impact of environmental 
chemicals on fertility and pregnancy outcomes 
among couples seeking fertility treatment. All 
women in the larger study who underwent 
at least one IVF cycle and had urinary BPA 
analyzed were included in the present analysis. 
Study participants were female partners of cou­
ples seeking infertility evaluation and treatment 
at the Massachusetts General Hospital (MGH) 
Fertility Center, Boston, Massachusetts. 
Couples were recruited between November 
2004 and April 2010. Women 18–45 years 
of age who used their own oocytes (eggs) for 
IVF were eligible. The women were followed 
from study entry through each of their IVF 
cycles until they had a live birth or discontin­
ued treatment at the MGH Fertility Center. 
The study was approved by the Institutional 
Review Boards of the Massachusetts General 
Hospital, Harvard School of Public Health 
(HSPH), and the Centers for Disease Control 
and Prevention (CDC). All participants pro­
vided an informed consent after the study pro­
cedures were explained by a research nurse and 
all questions were answered.
At recruitment, a brief, nurse­  administered 
questionnaire was used to collect data on 
demographics, medical history, and lifestyle. 
Women also completed a detailed take­home 
questionnaire with additional questions on life­
style factors, occupation, and medical history 
(completed by > 90% of participants). Clinical 
information was obtained from the electronic 
medical record, and infertility diagnoses were 
classified according to the Society for Assisted 
Reproductive Technology (SART) definitions.
Treatment protocols and clinical IVF 
measures. All women were initially treated 
with a cycle of oral contraceptive pills (OCP) 
to suppress ovulation unless it was contra­
indicated. The day of OCP­induced menses 
was referred to as cycle day 1 of the treatment 
cycle, the day after was cycle day 2 and so on. 
The patient was then monitored at cycle day 3 
at the clinic to ensure ovarian suppression 
before beginning controlled ovarian stimula­
tion with follicle­stimulating hormone (FSH) 
and gonadotropin­  releasing hormone (GnRH) 
agonists or antagonists. Patients were moni­
tored as needed during gonadotropin stimu­
lation for serum estradiol (E2), follicle size 
measurements, folli  cle count, and endometrial 
thickness through 2 days before the egg­re­
trieval procedure. Human chorionic gonado­
tropin (hCG), a hormone similar to luteinizing 
hormone (LH), was administered (hCG trig­
ger) approximately 36 hr before the scheduled 
egg­retrieval procedure to induce ovulation. 
Measurements of serum FSH and E2, and 
details of egg retrieval have been previously 
described (Mok­Lin et al. 2010). Patients 
underwent one of three IVF treatment proto­
cols: a) luteal­phase GnRH agonist protocol 
using low­, regu  lar­, or high­dose leuprolide 
(Lupron) with pituitary desensitization begun 
in the luteal phase; b) follicular­phase GnRH­
agonist/Flare protocol, in which Lupron was 
begun on day 2 of the follicular phase at 
20 units and decreased to the standard dose 
of 5 units on day 5; and c) GnRH­antagonist 
protocol, in which GnRH­antagonist was 
begun when the lead follicle reached 14 mm in 
size and/or E2 levels were ≥ 1,000 pg/mL. The 
antagonist and flare protocols were primarily 
for poor responders. The flare protocol is indi­
cated for women > 40 years of age with very 
poor ovarian response (i.e., inadequate follicle 
recruitment after controlled ovarian stimula­
tion with gonadotropins and low peak E2 level 
at time of hCG trigger), whereas the antago­
nist protocol is used in women < 40 years of 
age with diminished ovarian reserve and poor 
ovarian response.
Endometrial thickness (millimeters) 
was measured by transvaginal ultrasound 
scan (7.5 MHz frequency; GE Logiq 3/5; 
GE Healthcare, Waukesha, WI) before the 
administration of hCG, which corresponded 
to 36 hr before the egg­retrieval procedure. 
Women with endometrial thickness < 7 mm 
typically did not undergo a transfer and their 
embryos were frozen. Following the day of egg 
retrieval, patients were prescribed progesterone 
(P), usually by intramuscular adminis  tration 
(50 mg/day). Nine days after egg retrieval, 
patients began transdermal E2 (Vivelle patches; 
Novartis Pharmaceuticals Corp., East Hanover, 
NJ) at a dose of 0.2 mg every other day. Both 
P and E2 were administered to hormonally 
prime the endometrium for embryo transfer.
Embryos were evaluated by an embryolo­
gist and selected for uterine transfer on day 2, 
3, or 5 of embryo maturation in culture. A 
day­2 transfer was performed when the patient 
had only one or two embryos for transfer. 
Because there were few day­2 transfers (n = 13 
IVF cycles) and they represent patients with 
poorer expected outcomes, they were excluded 
from these analyses and are not included in the 
180 cycles. Implantation failure was defined as 
a serum β­hCG level < 6 mIU/mL typically 
measured 17 days (97% measured by day 17, 
range 15–20 days) after egg retrieval.
Urine sample collection and urinary bis-
phenol A concentrations. The 137 enrolled 
women provided ≤ 2 spot urine samples per 
IVF cycle, the first collected between cycle 
day 3 and day 9 of the treatment cycle, and 
the second on the day of the egg­retrieval pro­
cedure, typically before the procedure. Urine 
was collected in a sterile clean polypropylene 
specimen cup. Specific gravity (SG) was mea­
sured at room temperature using a handheld 
refractometer (National Instrument Co. Inc., 
Baltimore, MD) calibrated with deionized 
water before each measurement. The urine was 
divided into aliquots and frozen and stored at 
–80°C. Samples were shipped on dry ice over­
night to the CDC where they were stored at 
≤ –40°C until analysis.
The urinary concentration of free and con­
jugated BPA species (total BPA) was measured 
using online solid phase extraction (SPE) 
coupled to isotope dilution–high performance 
liquid chromatography (HPLC)–tandem mass 
spectrometry (MS/MS) as described before 
(Ye et al. 2005). First, 100 µL of urine was 
treated with β­glucuronidase/sulfatase (Helix 
pomatia, H1; Sigma–Aldrich, St. Louis, MO) 
to hydrolyze the BPA­conjugated species. BPA 
was then retained and concentrated on a C18 
reversed­phase­size­exclusion SPE column 
(Merck KGaA, Darmstadt, Germany), sepa­
rated from other urine matrix components 
using a pair of monolithic HPLC columns 
(Merck KGaA), and detected by negative ion–
atmospheric pressure chemical ionization–
  MS/MS. The limit of detection (LOD) for 
BPA was 0.4 µg/L. In addition to study 
samples, each analytical run included low­
concentration and high­concentration quality 
control materials, prepared with spiked pooled 
human urine, and reagent blanks to assure 
the accuracy and reliability of the data (Ye 
et al. 2005). BPA concentrations < LOD were 
assigned a value equal to the LOD divided by 
√
– 2 (Hornung and Reed 1990) before adjust­
ment for urine dilution by SG, as described 
previously (Meeker et al. 2010).
Statistical analysis. Characteristics of the 
women and IVF cycles were summarized using 
means, standard deviations, and percentages, 
as appropriate. The geometric mean of the 
SG­adjusted BPA concentrations from two 
spot–urine samples collected during each IVF 
cycle was used as a measure of cycle­specific 
urinary BPA concentration. The distribution 
of these geometric mean BPA concentrations 
was summarized using percentiles.
Multivariate generalized estimating equa­
tion (GEE) models for repeated measures were 
used to evaluate the association between cycle 
specific urinary SG­adjusted BPA concentra­
tions and potential risk factors for implan­
tation failure. We used an autoregressive 
correlation structure to account for correla­
tion between outcomes across repeated IVF 
cycles within the same woman. We modeled 
SG­adjusted urinary BPA concentrations in 
quartiles. Age (≥ 37 years or < 37 years), and 
day of embryo transfer (day 5 vs. day 3) were 
retained in the final model because of their 
biological and clinical relevance as indicated 
in previous studies (Giorgetti et al. 1995; 
Rehman et al. 2007).
Other variables considered as potential 
confounders included the number of embryos 
transferred (single vs. multiple); IVF protocol Ehrlich et al.
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type (flare/antagonist vs. regular luteal phase 
protocol); day­3 serum FSH level (inter­
national units per liter, a measure of ovarian 
reserve); peak serum E2 (this corresponded to 
the last serum E2 measurement, 2 days before 
egg retrieval); endometrium thickness (< 9 mm 
vs. ≥ 9 mm); smoking (ever vs. never smoker); 
and body mass index (BMI) [overweight/obese 
(BMI ≥ 25 kg/m2) vs. normal/underweight 
(BMI < 25 kg/m2)]. Covariates that predicted 
implantation failure with p < 0.2 in uni  variate 
models and present in ≥ 5% of the cohort 
were evaluated for inclusion in the multi­
variate model using backward selection, and 
they were retained in the final model if their 
p was ≥ 0.10 or if the effect estimate changed 
by > 10% when the covariates were removed. 
A test for trend was performed to determine if 
there was a linear dose–response relationship 
between quartiles of urinary BPA and implan­
tation failure. The trend test was performed 
by modeling the BPA quartiles as an ordinal 
categorical variable, using the integer values 
0, 1, 2, and 3 for BPA quartiles 1, 2, 3, and 4, 
respectively.
As an alternative to the GEE model 
approach based on a logistic link, log bino­
mial models for the relative risk were also fit. 
Because these models did not always con­
verge, but yielded similar results when they 
did, they are not presented here. In addition, 
analyses restricted to first cycles only were 
also performed.
Because the choice of IVF treatment pro­
tocol used in a given cycle is determined by 
the patient’s anticipated probability of suc­
cess based in part on past implantation failures 
and because past urinary BPA concentrations 
may be associated with past implantation fail­
ures and correlated with current BPA con­
centrations, we considered protocol type as 
a potential intermediate on the causal path­
way between urinary BPA concentration and 
implantation failure. We therefore present 
model results both adjusted and unadjusted for 
treatment protocol. We also conducted a strati­
fied analysis by type of treatment protocol. All 
data analyses were performed using SAS   version 
9.2 (SAS Institute Inc., Cary, NC).
Results
The 137 women included in this analysis 
were on average 35.8 years of age, 87% were 
Caucasian, and < 5% were current smokers 
(Table 1). Approximately one­third of the 
couples had a primary SART diagnosis of 
female infertility, a third had male factor 
infertility, and a third had unexplained infer­
tility. Women who had ever had a treatment 
cycle that resulted in an implantation failure 
were on average 2 years older than those who 
had never experienced an implantation failure. 
The primary treatment protocol for the 180 
IVF cycles undergone by the 137 study par­
ticipants was the luteal phase GnRH agonist 
protocol (61% of cycles; Table 2). Only 13% 
of the embryo transfers were single embryo 
transfers, and one third of the transfers were 
on day 5 at the blastocyst stage.
The 325 urine samples provided by the 
137 women had urinary BPA concentrations 
that were comparable to general population 
concentrations from NHANES participants. 
The geometric mean was 1.53 µg/L compared 
with 1.97 µg/L for females in NHANES 
2007–2008 (CDC 2011) (Table 3). Two 
urine samples were collected in 80% 
(144/180) of cycles. No significant differences 
(at p < 0.05) in baseline characteristics were 
noted between women who contributed one 
Table 1. Subject demographics and infertility diagnoses among 137 women undergoing IVF [n (%)].
Implantation failure since entry to study
Characteristic Total (n = 137) Ever had (n = 43) Never had (n = 94)
Age [years; mean ± SD (range)] 35.8 ± 4.0 (21 – 44) 37.0 ± 4.8 (21 – 44) 35.2 ± 3.5 (28 – 43)
< 37 79 (58) 17 (40) 62 (66)
≥ 37 58 (42) 26 (60) 32 (34)
BMIa [kg/m2; mean ± SD (range)] 24.7 ± 5.0 (16.5 – 42) 26.2 ± 5.5 (17.5 – 42.3) 23.9 ± 4.6 (16.5 – 39.1)
≥ 25 45 (33) 18 (42) 27 (29)
Race
White 119 (87) 35 (81) 84 (89)
Black/African American 5 (4) 2 (5) 3 (3)
Asian 8 (6) 2 (5) 6 (6)
Hispanic/other 5 (4) 4 (9) 1 (1)
Smoking
Never smoker 98 (72) 32 (74) 66 (70)
Ever smoker 39 (28) 11 (26) 28 (30)
Current smoker 5 (4) 2 (5) 3 (3)
Former smoker 34 (25) 9 (21) 25 (27)
SART diagnosisb
Female factor infertility 49 (36) 20 (46) 29 (31)
Diminished ovarian reserve 13 (26) 7 (35) 6 (21)
Ovulation disorders 14 (29) 2 (10) 12 (41)
Endometriosis 11 (22) 6 (30) 5 (17)
Uterine disorders 1 (2) 0 (0) 1 (3)
Tubal factor 10 (20) 5 (25) 5 (17)
Male factor infertility 49 (36) 13 (30) 36 (38)
Unexplained 36 (26) 7 (16) 29 (31)
Otherc 3 (2) 3 (7) 0 (0)
Due to rounding, percentage totals may not sum to 100%. 
aBMI missing for 1 subject from implantation group. bPrimary diagnosis of infertility. cOther SART diagnoses: balanced 
translocation, Canavan’s disease, irregular antibodies.
Table 2. Treatment protocols, cycle characteristics, and pregnancy outcomes for 180 IVF cycles among 
137 women [n (%)].
Characteristic IVF cyles  Implantation failure (n = 75) Implantation (n = 105)
IVF protocol
Luteal phase 109 (61) 33 (44) 76 (72)
Low-dose leuprolide lupron 102 (57) 31 (41) 71 (68)
Regular-dose leuprolide lupron 7 (4) 2 (3) 5 (5)
Flare 47 (26) 27 (36) 20 (19)
Antagonist 24 (13) 15 (20) 9 (9)
Day 3 FSH (IU/L)
Mean ± SD 7.3 ± 2.3 7.6 ± 2.3 7.1 ± 2.3
Range 1.0–15.2 1–15.2 1–15.2 
Peak E2 (pg/mL)a
Mean ± SD 2,051 ± 819 2,040 ± 874 2,060 ± 783
Range  551–4,455 551–4,126 635–4,455
Endometrial thicknessa
Thin (≤ 8 mm) 35 (19) 16 (21) 19 (18)
Mean ± SD 10.3 ± 2.0 10.1 ± 1.9 10.4 ± 2.1
Range 6–19 7–15 6–19
Day of embryo transfer
3 120 (67) 57 (76) 63 (60)
5 60 (33) 18 (24) 42 (40)
No. of embryos transferred
1 24 (13) 11 (15) 13 (12)
2 109 (61) 39 (52) 70 (67)
≥ 3 47 (26) 25 (33) 22 (21)
Due to rounding, percentage totals may not equal 100%. 
aMissing 10 peak E2 and endometrial thicknesses; the mean   number of cycles was 1.3 cycles/woman.Bisphenol A and implantation failure in women
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sample as compared with two urine samples 
during their treatment cycle (data not shown). 
For the 20% of cycles with one urine sample, 
the BPA concentration for that single urine 
sample was used as the cycle­specific urinary 
BPA concentration. Detectable concentrations 
of BPA were measured in 88% (287/325) of 
samples (Table 3).
In unadjusted logistic regression models, 
women ≥ 37 years of age had more than twice 
the odds of implantation failure as compared 
with women < 37 years of age, and women 
on a flare or antagonist protocol had a more 
than three times the odds of implantation 
failure as compared with women on the luteal 
phase protocol (Table 4). In IVF cycles in 
which the embryo transfer occurred on day 5, 
there was a 50% decreased odds of implanta­
tion failure compared with a day­3 embryo 
transfer. Day­3 FSH (international units per 
liter) was marginally associated with increased 
odds of implantation failure, but showed no 
association after adjustment for other covari­
ates (age, day of embryo transfer, and IVF 
protocol type) in the multivariate model. The 
remaining covariates were not significantly 
associated with implantation on univariate 
analyses (p < 0.2) and therefore did not qual­
ify for inclusion in our multi  variate model. 
Urinary BPA concentrations were significantly 
higher in women who underwent a low 
responder treatment protocol as compared 
with the regu  lar luteal phase protocol (4.08 
vs. 2.61 µg/L, p < 0.001). BPA concentrations 
did not vary significantly by levels of other 
covariates of interest that were considered for 
inclusion in the multivariable model.
In the unadjusted model, the odds of 
implantation failure increased linearly with 
increasing quartiles of urinary BPA con­
centrations: odds ratios (OR) [95% confi­
dence interval (CI)] were 1.01 (0.38, 2.66), 
1.57 (0.70, 3.52), and 2.38 (0.97, 5.83) for 
quartiles 2, 3, and 4, respectively, compared 
with the lowest quartile (p­trend = 0.03) 
(Table 4 and Figure 1). Results were simi­
lar after adjusting for older age (> 37 years) 
and day of embryo transfer (day 5 vs. day 3), 
although slightly attenuated for the fourth ver­
sus first quartile of exposure (p­trend = 0.06). 
Finally, after adjustment for IVF protocol, 
the associations were further attenuated but 
remained consistent with a positive linear 
dose–response relationship.
In models stratified by IVF protocol, there 
was a stronger association of urinary BPA con­
centration with implantation failure among 
women undergoing flare/antagonist protocols 
(n = 51 women, 71 cycles) compared with 
women undergoing the luteal protocol (n = 95 
women, 109 cycles). Nine women were in the 
luteal protocol group for one cycle and the 
flare/antagonist group for a subsequent cycle. 
Among women in the flare/antagonist proto­
col, the ORs (95% CI) for implantation failure 
by quartile of urinary BPA concentration, after 
adjustment for age (years) and day of embryo 
transfer (day 5 vs. day 3), were 1.50 (0.26, 
8.58), 2.12 (0.47, 9.62), and 3.59 (0.74, 17.43) 
for quartiles 2, 3, and 4, respectively, compared 
with the lowest quartile (p­trend = 0.07). In 
contrast, corresponding estimates for women 
in the luteal protocol group were 0.68 (0.13, 
3.55), 1.02 (0.35, 2.95), and 1.04 (0.36, 3.04) 
for quartiles 2, 3, and 4, respectively, com­
pared with the lowest quartile (p­trend = 0.83). 
Women treated with the alternative flare or 
antagonist protocols were more likely than 
women treated with the luteal protocol to have 
had past IVF treatment cycle failures (73% 
vs. 34%), diminished ovarian reserve (mean 
day­3 FSH 8.8 IU/L vs. 6.6 IU/L), and dimin­
ished ovarian response to controlled ovarian 
FSH hyperstimulation (mean peak serum E2 
1,735 pg/mL vs. 2,258 pg/mL, mean number 
of eggs retrieved 7.6 vs. 12.7). Finally, women 
on the alternative protocol were almost 4 years 
older than women on the luteal phase protocol 
(mean age 38.1 years vs. 34.3 years).
Discussion
In the present study, the association between 
urinary BPA concentrations and implanta­
tion failure increased with increasing urinary 
BPA quartiles after adjusting for age and day 
of embryo transfer. Women in the fourth 
quartile of exposure (SG­adjusted urinary BPA, 
3.80  –26.48 µg/L) had almost twice the odds 
of implantation failure as women in the first 
quartile of exposure (≤ 1.69 µg/L). This trend 
remained after adjusting for IVF protocol.
Table 3. Distribution of cycle-specific urinary BPA concentrations (µg/L) among 137 women undergoing 
180 IVF cycles (325 urine samples).
Percentile
Detection rate GM (SD) Min 10th 25th 50th 75th 90th 95th Max
BPA 88% 1.53 (2.22) < LOD 0.60 0.89 1.50 2.40 3.76 6.04 22.07
SG-adj BPA 2.56 (1.87) < LOD 1.27 1.69 2.33 3.79 5.91 7.82 26.48
Abbreviations: < LOD, below limit of detection (0.4 µg/L); Max, maximum; Min, minimum; SG-adj BPA, specific-gravity–
adjusted BPA concentrations. All values below LOD were assigned a value equal to the LOD divided by √– 2. Nine (5%) 
cycle-specific BPA concentrations were < LOD and are included in the percentiles. Thirty-eight (12%) individual urine 
samples had BPA concentrations < LOD. There was an 88% detection rate for all individual urine samples [SG range 
(1.001–1.035)].
Table 4. Crude and adjusted ORs (95% CIs) for associations of quartiles of urinary BPA concentrations 
with implantation failure among 137 women undergoing 180 IVF cycles.
Characteristic n Unadjusted p-Value Adjusteda
IVF-protocol 
adjustedb
SG-adjusted BPA quartiles (range µg/L)
1 (≤ 1.69) 45 Reference Reference
2 (1.70–2.33) 45 1.01 (0.38, 2.66) 1.02 (0.35, 2.95) 1.05 (0.36, 3.03)
3 (2.34–3.79) 46 1.57 (0.70, 3.52) 1.60 (0.70, 3.78) 1.52 (0.65, 3.55)
4 (3.80–26.48) 44 2.38 (0.97, 5.83) 2.11 (0.84, 5.31) 1.90 (0.73, 4.96)
p-Trend 0.03 0.06 0.12
Age (≥ 37 vs. < 37 years) 2.22 (1.15, 4.28) 0.02 1.89 (0.97, 3.65) 1.50 (0.76, 2.95)
Embryo transfer day (day 5 vs. day 3) 0.48 (0.24, 0.95) 0.03 0.53 (0.26, 1.08) 0.68 (0.32, 1.45)
IVF protocol (flare/antagonist vs. luteal) 3.16 (1.70, 5.87) < 0.001 2.09 (1.03, 4.24)
No. embryos transferred (1, ≥ 2) 0.67 (0.29, 1.54) 0.35
Day-3 FSH (IU/L) 1.87 (0.95, 1.28) 0.19
Peak E2 (pg/mL) 1.00 (0.99, 1.00) 0.68
Endometrial thickness (≤ 8 mm vs. > 8 mm) 1.50 (0.69, 3.24) 0.30
Ever smoker vs. never smoker 1.09 (0.55, 2.16) 0.80
BMI (≥ 25 kg/m2 vs. < 25 kg/m2)c 1.35 (0.69, 2.64) 0.38
Urine collection year (continuous) 0.84 (0.56, 1.27) 0.42
aAdjusted for age [≥ 37 years vs. < 37 years (referent group)] and day of embryo transfer [day 5 vs. day 3 (referent 
group)]. bAdjusted for age (≥ 37 years vs. < 37 years), day of embryo transfer (day 5 vs. day 3), and IVF protocol [flare/
antagonist vs. luteal (referent group)]. cOne missing value.
Figure 1. Crude and adjusted OR (95% CI) for the 
associations of quartiles (Q) of urinary BPA concen-
trations in relation to implantation failure among 137 
women undergoing 180 IVF cycles. 
aAdjusted for age (≥ 37 years vs. < 37 years) and day 
of embryo transfer (day 5 vs. day 3). bAdjusted for age 
(≥ 37 years vs. < 37 years), day of embryo transfer (day 5 
vs. day 3), and IVF protocol (flare/antagonist vs. luteal).
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After stratifying by protocol type, we 
identified a potentially more sensitive subgroup 
of women. There was a stronger association 
between urinary BPA concentrations and 
implantation failure among women undergoing 
the flare or antagonist protocol (alternative/
low responder protocol) as compared with 
women under  going the luteal protocol, 
though numbers were small within strata and 
there was considerable overlap in 95% CI 
for corresponding estimates between the 
two groups. Women on the flare/antagonist 
protocol were older with diminished ovarian 
reserve and response than women on the luteal 
protocol. Although speculative, diminished 
ovarian reserve may impart increased 
sensitivity to implantation failure in relation to 
BPA exposure.
Implantation in animals and humans is 
hormonally modulated by E2 and P via regu­
lation of expression of endometrial proteins 
that play an important role in endometrial 
receptivity at the time of implantation (Cooke 
et al. 1997). Increased secretion of E2 in the 
preovulatory phase is necessary to stimulate 
the proliferation and differentiation of the 
uterine epithelial cells. In the luteal phase, 
continued production of P stimulates the 
proliferation and stimulation of the stromal 
cells, thus preparing the endometrium for suc­
cessful embryo implantation (Norwitz et al. 
2001). E2 and P also play a role in embryo 
development and embryo migration through 
the oviduct, though the latter is less relevant 
in women undergoing IVF because eggs are 
retrieved from the ovary and cultured embryos 
are transferred directly into the uterine cav­
ity, bypassing the oviduct. At the level of the 
embryo, E2 plays an important role in the 
activation of the dormant blastocyst, which 
is critical for successful implantation (Paria 
et al. 1993). Previous findings from the study 
cohort indicated that higher urinary BPA con­
centrations were associated with decreased 
peak serum E2 levels and decreased number 
of eggs retrieved in women undergoing IVF 
(Mok­Lin et al. 2010).
Evidence from animal studies sug­
gests that BPA’s estrogenic properties may 
disrupt implantation via two mechanisms 
(Berger et al. 2007, 2008, 2010; Varayoud 
et al. 2011): a) accelerating the rate of blasto­
cyst development and thus leading to mis­
match in timing with the appropriate uterine 
receptivity window (Takai et al. 2001), and 
b) directly decreasing uterine receptivity to 
blastocyst implantation (Berger et al. 2010). 
Environmentally relevant doses or low concen­
trations (1–3 nM) of BPA have been shown to 
significantly increase the developmental rates 
of two­cell mouse embryos to blastocysts. At 
a high concentration (100 mM), BPA sig­
nificantly decreased the in vitro developmental 
rates of the embryos (Takai et al. 2000). This 
could result in an embryo uterine mismatch 
and impair successful implantation.
In a recent study, high doses of BPA 
administered subcutaneously (3.375, 6.75, 
and 10.125 mg/day) to mice during the 
peri  ­  implantation phase resulted in a dose­
  dependent increase in luminal area (i.e., altered 
endo  metrial morphology) and decreased 
expression of estrogen receptor α (ERα) and 
progesterone receptor (PR) via BPA action on 
the ER and decreased PR expression leading 
to implantation failure (Berger et al. 2010). 
Timing of exposure was critical, and a single 
6.75­mg dose of subcutaneously administered 
BPA on day 0 or 10.125 mg on day 1 of preg­
nancy was sufficient to significantly reduce 
the number of implantation sites in mice. 
However, when the same dose was adminis­
tered on day 2 of pregnancy, it had no effect 
on the number of implantation sites observed 
(Berger et al. 2008). In contrast to humans, in 
mice, implantation can occur as late as day 4 
of pregnancy because blastocysts can remain in 
a state of quiescence until uterine conditions 
are optimal for embryo implantation (Carson 
et al. 2000). A previous study by Berger and 
colleagues found that an average of 68.84 mg 
of BPA ingested per day (substantially higher 
than typical daily doses to which humans 
are exposed) resulted in a complete block of 
implantation, whereas comparable results 
were achieved with a dose of only 6.75 mg 
administered via subcutaneous administration 
(Berger et al. 2007). The most common route 
of human exposure to BPA is through inges­
tion (Vandenberg et al. 2007).
A recent study in rats showed that BPA 
at doses as low as 0.05 mg/kg/day [the U.S. 
Environmental Protection Agency (EPA) oral 
reference dose (U.S. EPA 1993)] resulted in 
decreased Hoxa 10 expression, an essential 
transcription factor required for endometrial 
receptivity and implantation (Varayoud et al. 
2011). Down­regulation of the ERα and PR 
was also observed, accompanied by a signifi­
cantly decreased number of implantation sites.
One potential limitation of the present 
study is that there is within­individual vari­
ability in urinary BPA concentrations and col­
lecting single spot urine samples may result in 
exposure misclassification (Braun et al. 2011; 
Ye et al. 2011). However, a previous study in 
our cohort showed that a single urine sam­
ple had moderate sensitivity for predicting an 
individual’s longer­term exposure over several 
weeks or months (Mahalingaiah et al. 2008). 
The sensitivity of classifying a subject in the 
highest tertile using a single urine sample was 
0.64. In the present study, during each cycle, 
urine samples were collected twice over a 
period of 2 weeks. The Spearman correlation 
of within­cycle urinary BPA concentrations 
for this short time interval was 0.18. Although 
two measures of urinary BPA concentration 
are better than a single spot sample at clas­
sifying BPA exposure, we cannot be certain 
that we collected samples within the relevant 
window of exposure given the short half­life of 
BPA (Volkel et al. 2002) and its high variabil­
ity over time. The exact timing of urine collec­
tion was dependent on the date and time of 
medical appointments and egg­retrieval proce­
dures and were not necessarily first morning or 
fasting urines.
Another potential limitation is uncertainty 
regarding the generalizability of the results to 
women who conceive naturally. It is possible 
that women undergoing IVF may be more 
sensitive to BPA exposure for a variety of rea­
sons, including their underlying infertility, 
the in vitro conditions of early embryonic 
development, or the ovarian hyperstimulation 
protocols. Despite uncertainty regarding gen­
eralizability to women conceiving naturally, 
using IVF as a model to study human repro­
duction has several strengths. This includes 
the assessment of early developmental end 
points that are not observable in women 
conceiving naturally but have been shown 
to be susceptible to environmental chemi­
cal exposure in experimental studies (Berger 
et al. 2007, 2008, 2010; Hunt et al. 2003; 
Takai et al. 2000). Furthermore, because 
approximately 10–15% of the population in 
the United States and developed countries are 
infertile (Fritz and Speroff 2011), the results 
of the present study may be generalizable to 
a large portion of the general population. 
Additional strengths include the preconcep­
tion prospective study design, allowing us 
to collect exposure information before the 
outcome of interest and performing accurate 
clinical ascertainment of implantation fail­
ure. One of the limitations of conventional 
epidemiologic designs in naturally conceiving 
women is that it is logistically challenging and 
expensive to collect and analyze daily urines 
for multiple months to assess implantation 
failure (Wilcox et al. 1988).
Finally, by applying a GEE approach to 
account for correlated outcomes across cycles 
within a given woman, we were able to opti­
mize all the data available to us, which is par­
ticularly important given the relatively small 
size of our sample population. Alternative 
modeling approaches such as nonlinear mixed 
effect models may be preferable, particularly 
given the potential for ORs to overestimate 
relative risks for common outcomes (e.g., the 
42% implantation failure in our study popu­
lation), but they could not be applied given 
the limited sample size. However, results 
based on only first cycle and on log binomial 
models were consistent with those presented.
As recruitment continues and our study 
population increases, we plan to extend these 
analyses to explore the contribution of the 
male gametes and male exposures to BPA to Bisphenol A and implantation failure in women
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implantation failure. We also plan to explore 
the association of maternal and paternal BPA 
exposure with embryo quality and cleavage 
rate to further understand the potential affect 
of BPA on implantation and fertility.
In conclusion, these preliminary find­
ings are, to the best of our knowledge, the 
first human data on the association between 
environ  mental exposure to BPA and implanta­
tion failure. The results suggest a positive lin­
ear dose–response association between urinary 
BPA concentrations and implantation failure 
among women undergoing IVF treatment.
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